New assay to test KRAS mutations in ctDNA

Version:1.0 StartHTML:0000000211 EndHTML:0000039240 StartFragment:0000038490 EndFragment:0000039200 SourceURL:file:///C:/Users/mlin36/Desktop/Molecular%20Pathol%20Blog/DEcember%20KRAS/December%202018.docx

In December 2018, the Molecular Diagnostics Lab is introducing a droplet digital PCR assay to monitor KRAS mutation in the circulating tumor DNA (ctDNA). The primary use of the test is for predicting recurrence and monitoring therapy of pancreatic ductal adenocarcinomas. The test requires 40 mls of EDTA anticoagulated blood that must be received in the laboratory the same day of the blood draw.